Results 201 to 210 of about 66,268 (303)

Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1287-1308, May 2026.
The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia,
Paraskevi Papakyriakopoulou   +2 more
wiley   +1 more source

Therapeutic Potential of Origanum majorana L. Essential Oil in Diabetes Mellitus: Insights From GC–MS Characterization, In Vivo Hypoglycaemic Studies, and In Silico Analyses

open access: yesChemistry &Biodiversity, Volume 23, Issue 5, May 2026.
Exploring the chemical profile and biological property of O. majorana EO. ABSTRACT Diabetes mellitus is a widespread metabolic disorder characterized by impaired glucose regulation. This study investigated the chemical composition and antidiabetic potential of Origanum majorana essential oil (EO) using integrated in vitro, in vivo, and computational ...
Mahmoud Houas   +12 more
wiley   +1 more source

Myelin Oligodendrocyte Glycoprotein Antibody‐Associated Cerebral Cortical Encephalitis: A Comparative Study With Antibody‐Negative and Non‐MOG Antibody‐Positive Cortical Encephalitis in Chinese Adults

open access: yesCNS Neuroscience &Therapeutics, Volume 32, Issue 5, May 2026.
MOG antibody‐associated cortical encephalitis (MOG‐CCE) presents a distinct clinical phenotype characterized by seizure‐dominant onset, unilateral cortical lesions, and favorable immunotherapy response, highlighting the diagnostic and prognostic value of antibody profiling in autoimmune cortical encephalitis.
Qing Yin   +7 more
wiley   +1 more source

Emulating Six Cardiovascular Outcome Trials of Antidiabetic Drugs in Individuals with Type 2 Diabetes: Analyses Based on Real‐World Databases from Korea and Taiwan

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1265-1274, May 2026.
With the increasing volume of clinical evidence derived from large‐scale Asian real‐world data (RWD) and the growing interest in its use in regulatory decision‐making, it is important to conduct benchmarking exercises that evaluate whether studies using Asian RWD can generate similar conclusions as randomized controlled trials (RCTs).
Hwa Yeon Ko   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy